46 results on '"Castagna, Luca"'
Search Results
2. La storia come magistero d'orizzonti ed esercizio di virtù civili
- Author
-
Castagna, Luca
- Subjects
ricerca storica ,lezione ,metodologia - Published
- 2023
3. 'Relazioni chimiche': Michele Sindona, l'affaire Ronson e alcuni aspetti dell'industrializzazione lucana tra anni sessanta e settanta
- Author
-
Castagna, Luca
- Subjects
Basilicata ,Industrializzazione ,Stati Uniti d'America ,Sindona - Published
- 2022
4. Il sacro confine: note sulle origini della 'questione' cattolica negli Stati Uniti
- Author
-
Castagna, Luca
- Subjects
Storia degli Stati Uniti ,Cattolicesimo statunitense ,religione in età contemporanea ,politica americana - Published
- 2022
5. Verso la normalizzazione? Biden, papa Francesco e la Chiesa cattolica
- Author
-
Castagna, Luca
- Subjects
Vaticano ,Cattolicesimo statunitense ,politica internazionale ,presidenza statunitense ,Chiesa cattolica - Published
- 2021
6. Dal 'qui' all''altrove'...e ritorno: il filone internazionalistico
- Author
-
Castagna, Luca
- Subjects
storia globale ,storia americana ,storia delle storiografia - Published
- 2021
7. USA '900: una diplomazia moderna. Nazionalismo, internazionalismo e idealismo alle origini dell'impero americano (1898-1909)
- Author
-
Castagna, Luca
- Subjects
imperialismo americano ,politica estera statunitense ,presidenza americana - Published
- 2021
8. Liberty versus Freedom: il 'mosaico' statunitense tra immigrazione e nativismo
- Author
-
Castagna, Luca
- Subjects
Storia degli Stati Uniti d'America ,nativismo statunitense ,migration studies - Published
- 2021
9. Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
- Author
-
Castagna,Luca, Santoro,Armando, and Carlo-Stella,Carmelo
- Subjects
Journal of Blood Medicine - Abstract
Luca Castagna,1 Armando Santoro,1,2 Carmelo Carlo-Stella1,2 1Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan 20089, Italy; 2Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan 20090, ItalyCorrespondence: Luca CastagnaHumanitas Clinical and Research Center, IRCCS, Via Manzoni 56, Rozzano, Milan 20089, ItalyEmail luca.castagna@humanitas.itAbstract: Relapse/refractory Hodgkin lymphoma patients are still a clinical concern. Indeed, despite more effective first-line chemotherapy regimens and better stratification of unresponsive patients by clinical factors and use of early PET, roughly one-third of such patients need salvage chemotherapy and consolidation with high-dose chemotherapy. In this paper, the authors review the different salvage treatments, with special emphasis on newer combinations with brentuximab vedotin or check point inhibitors. The overall response rate is constantly increasing, with a complete remission rate approaching 80%. Functional response evaluation by PET imaging is a strong predictive factor of longer survival, and more sophisticated tools, such as detection of circulating tumour DNA, are emerging to refine the disease-status assessment after treatment. Consolidation by high-dose chemotherapy is still considered the standard of care in chemosensitive patients, leading to a high fraction of patients towards long-term disease control. Maintenance therapy with BV is now approved, reducing disease relapse/progression. An increasing number of Hodgkin lymphoma patients will be cured after first- and second-line therapy, and long-term toxicity needs to be continuously assessed and avoided.Keywords: Hodgkin lymphoma, refractory/relapsed disease, checkpoint inhibitors, brentuximab vedotin, high-dose chemotherapy
- Published
- 2020
10. Recensione: Massimo Saba, Santa Sede e Stati Uniti (1797-1942), Roma, Studium Edizioni, 2019, 126 pp., € 14,50
- Author
-
Castagna, Luca
- Subjects
Vaticano ,Stati Uniti d'America ,politica internazionale ,Chiesa cattolica - Published
- 2020
11. Un realistico disincanto: la questione religiosa nelle relazioni italoamericane in età liberale
- Author
-
Castagna, Luca
- Subjects
questione romana ,Relazioni italo-americane ,metodismo transoceanico ,anti-cattolicesimo statunitense ,politica vaticana - Published
- 2020
12. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide
- Author
-
Ruggeri, Annalisa, Labopin, Myriam, Bacigalupo, Andrea, Gülbas, Zafer, Koc, Yener, Blaise, Didier, Bruno, Benedetto, Irrera, Giuseppe, Tischer, Johanna, Diez-Martin, Jose Luiz, Castagna, Luca, Ciceri, Fabio, Mohty, Mohamad, Nagler, Arnon, Ruggeri, Annalisa, Labopin, Myriam, Bacigalupo, Andrea, Gülbas, Zafer, Koc, Yener, Blaise, Didier, Bruno, Benedetto, Irrera, Giuseppe, Tischer, Johanna, Diez-Martin, Jose Luiz, Castagna, Luca, Ciceri, Fabio, Mohty, Mohamad, and Nagler, Arnon
- Subjects
Adult ,Male ,Cancer Research ,Transplantation Conditioning ,Adolescent ,Haploidentical transplantation ,Stem cell source ,Graft vs Host Disease ,Posttransplantation cyclophosphamide ,Young Adult ,Humans ,acute graft-versus-host disease ,acute leukemia ,haploidentical transplantation ,posttransplantation cyclophosphamide ,stem cell source ,Cyclophosphamide ,Aged ,Bone Marrow Transplantation ,Retrospective Studies ,Peripheral Blood Stem Cell Transplantation ,Acute leukemia ,Acute graft-versus-host disease ,Middle Aged ,Myeloablative Agonists ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Combined Modality Therapy ,Survival Rate ,Leukemia, Myeloid, Acute ,Oncology ,Transplantation, Haploidentical ,Female ,Follow-Up Studies - Abstract
BACKGROUND: Incidence of graft-versus-host disease (GVHD) in haploidentical bone marrow (BM) transplants using posttransplantion cyclophosphamide (PT-Cy) is low, whereas GVHD using mobilized peripheral blood stem cells (PBSC) ranges between 30% and 40%. METHODS: To evaluate the effect of stem cell source in haploidentical transplantation with PT-Cy, we analyzed 451 patients transplanted for acute myeloid leukemia or acute lymphoblastic leukemia reported to the European Society for Blood and Marrow Transplantation. RESULTS: BM was used in 260 patients, and PBSC were used in 191 patients. The median follow-up was 21 months. Engraftment was lower in BM (92% vs 95%, P < 0.001). BM was associated with a lower incidence of stage II-IV and stage III-IV acute GVHD (21% vs 38%, P ⤠.01; and 4% vs 14%, P < .01, respectively). No difference in chronic GVHD, relapse, or nonrelapse mortality were found for PBSC or BM. The 2-year overall survival (OS) was 55% versus 56% (P = .57) and leukemia-free survival (LFS) was 49% versus 54% (P = .74) for BM and PBSC, respectively. On multivariate analysis, PBSC were associated with an increased risk of stage II-IV (hazard ratio [HR], 2.1; P < .001) and stage III-IV acute GVHD (HR, 3.8; P < .001). For LFS and OS, reduced intensity conditioning was the only factor associated with treatment failure (LFS: HR, 1.40; P = .04) and relapse (HR, 1.62; P = .02). CONCLUSION: In patients with acute leukemia in first or second remission receiving haploidentical transplantation with PT-Cy, the use of PBSC increases the risk of acute GVHD, whereas survival outcomes are comparable.
- Published
- 2018
13. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
- Author
-
Bazarbachi, Ali, Boumendil, Ariane, Finel, Hervé, Mohty, Mohamad, Castagna, Luca, Blaise, Didier, Peggs, Karl, Afanasyev, Boris, Diez-Martin, J.L., Corradini, Paolo, Michonneau, David, Robinson, Stephen, Gutiérrez García, Gonzalo, Bonifazi, Francesca, Yakoub-Agha, Ibrahim, Gülbas, Zafer, Bloor, Adrian, Delage, Jeremy, Esquirol, Albert, Malladi, Ram, Scheid, Christof, El-Cheikh, Jean, Ghesquieres, Hervé, Montoto, Silvia, Dreger, Peter, Sureda, Anna, American University of Beirut [Beyrouth] (AUB), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Sorbonne Université (SU), Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), University College London Hospitals (UCLH), Hospital General Universitario 'Gregorio Marañón' [Madrid], Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University Hospitals Bristol, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Lapeyronie [Montpellier] (CHU), Queens Elizabeth Hospital [Birmingham], University Hospital of Cologne [Cologne], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Heidelberg University Hospital [Heidelberg], Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
- Subjects
Adult ,Male ,Salvage Therapy ,Immunoconjugates ,recurrence ,Hematopoietic Stem Cell Transplantation ,donor lymphocyte infusion ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,Middle Aged ,Hodgkin Disease ,Survival Analysis ,Young Adult ,Treatment Outcome ,allogeneic stem cell transplantation (allo-SCT) ,brentuximab vedotin ,Humans ,Female ,Neoplasm Recurrence, Local ,Hodgkin lymphoma ,Aged ,Retrospective Studies - Abstract
Background The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation-participating centers between 2010 and 2014. Results Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P
- Published
- 2019
14. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
- Author
-
Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, Giuseppe, Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Milone, G., Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, Placanica, Paola, Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, for the Gruppo Italiano Trapianto di Midollo Osseo, (GITMO), Associazione Microbiologi Clinici Italiani, (AMCLI), Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, G., Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, and Placanica, Paola
- Subjects
0301 basic medicine ,Male ,Transplantation Conditioning ,Drug Resistance ,Bacteremia ,0302 clinical medicine ,epidemiology ,Gram negative bacteremia ,multidrug resistance ,stem cell transplant ,survival ,Risk Factors ,Drug Resistance, Multiple, Bacterial ,Epidemiology ,Medicine ,Age Factor ,Prospective Studies ,Prospective cohort study ,Child ,Transplantation, Homologou ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,Bacterial ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,Transplantation, Autologou ,surgical procedures, operative ,Infectious Diseases ,Italy ,Child, Preschool ,Female ,medicine.symptom ,Multiple ,Autologous ,Human ,Homologous ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Adolescent ,030106 microbiology ,Population ,Transplantation, Autologous ,03 medical and health sciences ,Young Adult ,Internal medicine ,Gram-Negative Bacteria ,Gram-Negative Bacterial Infection ,Escherichia coli ,Humans ,Transplantation, Homologous ,Preschool ,education ,Aged ,Gram-Negative Bacterial Infections ,Infant ,Transplantation ,business.industry ,Risk Factor ,medicine.disease ,Prospective Studie ,Carriage ,Otitis ,business ,Settore MED/15 - Malattie del Sangue ,030215 immunology - Abstract
Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45–3.13; P Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.
- Published
- 2017
15. Recensione al volume: Tra pragmatismo e devozione. Le relazioni diplomatiche tra Santa Sede e Irlanda durante il pontificato di Pio XI (1922-1939)
- Author
-
Castagna, Luca
- Subjects
Politica internazionale ,Storia irlandese ,Diplomazia vaticana - Published
- 2018
16. Afterword, in Luca Castagna, A Bridge Across the Ocean: The United States and the Holy See between the Two World Wars (Catholic University Press: Washington DC)
- Author
-
Castagna, Luca and Fogarty, Gerald P.
- Published
- 2014
17. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry
- Author
-
Pedrazzoli, Paolo, Martinelli, Giovanni, Gianni, Alessandro Massimo, Da Prada, Gian Antonio, Ballestrero, Alberto, Rosti, Giovanni, Frassineti, Giovanni Luca, Aieta, Michele, Secondino, Simona, Cinieri, Saverio, Fedele, Roberta, Bengala, Carmelo, Bregni, Marco, Grasso, Donatella, De Giorgi, Ugo, Lanza, Francesco, Castagna, Luca, Bruno, Barbara, Martino, Massimo, and Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare
- Subjects
NO - Published
- 2014
18. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation
- Author
-
Blaise, Didier, Tabrizi, Reza, Boher, Jean-Marie, Le Corroller-Soriano, Anne-Gaëlle, Fegueux, Nathalie, Boiron, Jean-Michel, Furst, Sabine, Castagna, Luca, Chabannon, Christian, Boyer-Chammard, Agnès, Milpied, Noel, Labussière-Wallet, Hélène, Faucher, Catherine, Bardou, Valerie-Jeanne, Mohty, Mohamad, Michallet, Mauricette, Bay, Jacques-Olivier, Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Département d'Hématologie [CHU Haut Lévèque, Pessac], Hôpital Haut-Lévêque [CHU de Bordeaux], Bureau des essais cliniques et Unité de biostatistique [Marseille] (Institut Paoli-Calmettes), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Recherches en cancérologie, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), This work was supported by a grant from the Association pour la Recherche Contre le Cancer (Pole ARECA, 2001) and by a Programme Hospitalier de Recherche Clinique grant from the Ministry of Health (2001)., Dupuis, Christine, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer ,conditioning ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,reduced intensity ,allogenic hematopoietic stem cell transplantation ,socioeconomic evaluation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,hematologic malignancies - Abstract
International audience; BACKGROUND:The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain.METHODS:In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI.RESULTS:The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47% vs 27%; P = .01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65% vs 46%; P = .05) and a lower relapse rate (27% vs 54%; P < .01). However, the nonrelapse mortality rate was higher after BU-rATG than after TBI (38% vs 22%; P = .027). At 5 years, the overall and progression-free survival rates were 41% and 29%, respectively, and did not differ statistically between groups. A detrimental effect on some parameters of quality of life was more pronounced after BU-rATG, but recovery was identical in both groups. The mean total cost per patient, including the cost to treat disease progression post-transplantation, did not differ statistically between groups.CONCLUSIONS:Five years after transplantation, the BU-rATG regimen was associated with greater disease control. However, because of the higher nonrelapse mortality rate, this did not translate into better overall or progression-free survival.
- Published
- 2013
19. JC Virus Leuko-Encephalopathy in Reduced Intensity Conditioning Cord Blood Transplant Recipient with a Review of the Literature
- Author
-
El-Cheikh, Jean, Fürst, Sabine, Casalonga, Francois, Crocchiolo, Roberto, Castagna, Luca, Granata, Angela, Oudin, Claire, Faucher, Catherine, Berger, Pierre, Sarran, Anthony, and Blaise, Didier
- Subjects
viruses ,Case Reports - Abstract
We report here the case of progressive multifocal leukoencephalopathy (PML) related to human polyomavirus JC (JCV) infection after an allogeneic transplantation with umbilical cord blood cells in 59-year-old woman with follicular Non Hodgkin lymphoma. She presented with dysphagia and weakness; magnetic resonance imaging demonstrated marked signal abnormality in the sub-cortical white matter of the left frontal lobe and in the posterior limb of the right internal capsule. Polymerase chain reaction (PCR) analysis of the cerebrospinal fluid (CSF) was positive for John Cunningham (JC) virus. JC viral DNA in the CSF was positive, establishing the diagnosis of PML. Brain biopsy was not done. Extensive investigations for other viral infections seen in immuno-compromised patients were negative. The patient’s neurologic deficits rapidly increased throughout her hospital stay, and she died one month after the diagnosis. These findings could have practical implications and demonstrate that in patients presenting neurological symptoms and radiological signs after UCBT, the JCV encephalitis must be early suspected.
- Published
- 2012
20. Un Hemisferio para el Occidente: la estrategia rooseveltiana entre America Latina e Italia en vispera del Segundo Conflicto Mundial
- Author
-
Castagna, Luca
- Subjects
Europe ,Italy ,Stati Uniti ,good neighbor ,Franklin Delano Roosevelt ,America Latina - Published
- 2012
21. Verso il disgelo: Stati Uniti e Santa Sede, 1914-1940
- Author
-
Castagna, Luca, Scocozza, Antonio, and Rossi, Luigino
- Subjects
Vaticano ,M-STO/04 STORIA CONTEMPORANEA ,Stati Uniti - Abstract
2009 - 2010 Non esistendo uno studio critico d’insieme sulle relazioni intercorse tra gli Stati Uniti d’America e il Vaticano durante il ventennio infra-bellico, in questa ricerca si è tentato di colmare tale lacuna, ripercorrendone le tappe principali fino allo scoppio della Grande guerra e contestualizzandone l’evoluzione nell’ambito del convulso scenario internazionale degli anni Venti e Trenta del XX° secolo. L’obiettivo è quello di dimostrare come tale percorso di “riavvicinamento” temporaneo, in larga parte agevolato dal superamento delle barriere, politiche e culturali, che avevano storicamente sia impedito la completa assimilazione del cattolicesimo nella società statunitense, sia, di riflesso, alimentato una strenue reticenza a considerare il Vaticano quale possibile interlocutore alla stregua degli altri attori internazionali, avesse avuto una connotazione essenzialmente pragmatica ed una finalità chiaramente contrastiva nei confronti del nazi-fascismo e degli abomini da esso determinati. A tal scopo, partendo dalle suggestioni metodologico-interpretative offerte dalla letteratura esistente, si sono adoperate congiuntamente fonti primarie di diversa provenienza ed in parte inedite. Si è, infine, integrato l’utilizzo di alcune raccolte documentarie e di svariati periodici, questi ultimi in parte rinvenuti nei medesimi fondi archivistici e in parte consultati presso la Alderman Library della University of Virginia e la Public Library di New York... [a cura dell'Autore] IX n.s.
- Published
- 2011
22. Micafungin Versus Fluconazole Or Itraconazole For Prophylaxis Against Invasive Fungal Infections During Neutropenia In Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation
- Author
-
el-Cheikh Jean, Crocchiolo Roberto, Fürst Sabine, Bramanti Stefania, Sarina Barbara, Granata Angela, Faucher Catherine, Mohty Bilal, Bouabdallah Reda, Norbert Vey, Christian Chabannon, Santoro Armando, Blaise Didier, Castagna Luca, Harbi Samia, and Didier Blaise
- Subjects
medicine.medical_specialty ,business.industry ,Itraconazole ,Immunology ,Micafungin ,Cell Biology ,Hematology ,Total body irradiation ,Neutropenia ,medicine.disease ,Biochemistry ,Surgery ,Transplantation ,Regimen ,Internal medicine ,Medicine ,business ,Busulfan ,Fluconazole ,medicine.drug - Abstract
Objectives Over the past decade, invasive fungal infections (IFI) have remained an important problem in patients undergoing hematopoietic stem cell transplantation (HSCT). The optimal approach for prophylactic antifungal therapy has yet to be determined. Patients and Methods we conducted a retrospective, bi-institutional comparative clinical study, (Institut Paoli-Calmettes at Marseille France and Humanitas cancer center at Rozzano, Italy), and we compared the efficacy and safety of Micafungin 50mg/day (iv) with those of fluconazole (400mg/day) or itraconazole 200mg/day (iv) as prophylaxis for adult patients with various haematological diseases receiving haplo-identical allogeneic stem cell transplantation (haplo-SCT). Patients received prophylaxis with the beginning of the transplant conditioning regimen until the hospital discharge, or until occurrence of an IFI. We compared the incidence of proven or probable IFI (the primary end point) between the micafungin and fluconazole or itraconazole groups; death from any cause and time to death was secondary end points. Patients were followed for 100 days after haplo-SCT and for 30 days after the last dose of the prophylaxis drug administrated. Results From January 2009 to May 2013, a total of 99 patients were identified; 30 patients received micafungin, and 69 patients received fluconazole or itraconazole. 81 patients (82%) received a non myeloabaltive conditioning regimen (NMA), with Fludarabine, Cyclophosphamide and Total body irradiation (TBI) 2 Gy based , or Fludarabine, Busulfan, and Cyclophosphamide based (3%) or other (9%), while five patients (5%) received a thiotepa-based conditioning regimen. The patients and transplant details are shown in the table 1. Proven or probable invasive fungal infections were reported in 2 patients (7%) in the micafungin group and 8 patients (12%) in the fluconazole or itraconazole group (absolute reduction in the micafungin group, −5%; 95% confidence interval, 0.0565-3.1395, P=0.72). Fewer patients in the micafungin group had invasive aspergillosis (1 [3%] vs. 5 [7%], P=0.6). A total of 4 (13%) patients in the micafungin group and 23 (33%) patients in the fluconazole or itraconazole group received empirical antifungal therapy (P = 0.14). No serious adverse events related to treatment were reported by patients and there was no treatment discontinuation because of drug related adverse event in both groups. Overall Survival and disease free survival were similar among the two groups (P = 0.97). 6 patients (20%) in the micafungin group died within 100 days, as did 10 patients (14%) in the fluconazole or itraconazole group (P = 0.57). Interestingly the transplant related mortality (TRM) at 100 days was 0% in the micafungin group vs 13% in the second group [CI 95% (0-22)] (p=0,06), whereas the relapse or progression rate at 100 days was 27% vs. 8% respectively [CI 95% (14-44)] (p=0,14). Conclusions In patients undergoing to haplo-SCT, antifungal prophylaxis with micafungin is well tolerated and effective to prevent IFI. Furthermore, the incidence of IFI and invasive aspergillosis seems lower even if this did not attend statistical power, probably due to low number of patients. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
23. Use Of Unrelated Donors In Elderly Patients (age >60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies
- Author
-
Bouabdallah Reda, Mohty Bilal, Faucher Catherine, Fürst Sabine, Didier Blaise, Granata Angela, Devillier Raynier, Harbi Samia, Castagna Luca, Crocchiolo Roberto, Chabannon Christian, Vey Norbert, and El-Cheikh Jean
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Retrospective cohort study ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Surgery ,Fludarabine ,Transplantation ,Median follow-up ,Internal medicine ,medicine ,Cumulative incidence ,business ,Myelofibrosis ,Busulfan ,medicine.drug - Abstract
Objectives The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in older patients. However, there are only limited data on the feasibility and outcomes of URD HCT in elderly patients.The aim of the study was to compare the outcome in OS and PFS for patients transplanted using unrelated donor (URD) in patients age 60 or older. Patients and methods We retrospectively analyzed outcomes in 62 consecutive hematologic malignancy patients aged > or =60 years (median, 62 years; range: 60-70 years) undergoing reduced intensity conditioning regimens (RIC) from URD. In this study, URD was used only when a MRD was not available. Then we compared the outcome of 17 elderly patients (age >65 years) with 44 younger patients aged between 60 and 65 years. Patient, disease and transplant characteristics are shown in Table 1. Results No patients experienced graft rejection. The median HCT comorbidity index score was 2 (range, 0 to 6). With a median follow up of 36 months (range, 5-74), the cumulative incidence of grades II to IV acute GVHD was 28% and of grades III to IV acute GVHD, 13%. At 2 years, the cumulative incidence of chronic GVHD was 27%, progression-free survival (PFS) was 62%, overall survival (OS) was 63%, and relapse was 14%. Non relapse mortality (NRM) was 24% at 2 years. The cumulative incidence of grade II–IV Acute GVHD was 43% for the younger group and 17% for the older group (P = 0.056). The cumulative incidence of chronic GVHD was not different between the two groups (23% vs. 45% (p=0.3), respectively). Two-year OS and PFS was 57% versus 86% (P = 0.059) and 55% versus 86% (P = 0.03), in the younger and the older group respectively. The 2-year NRM and relapse was 26% versus 14% (P = 0.4) and 19% versus 0% (P = 0.04), in the younger and older group respectively. Conclusions This retrospective study suggest that RIC HCT from URD is a safe and effective option for patients aged > or =60 years or older, and in the absence of suitable related donors, well-matched URD may offer a very reasonable alternative, and that does not appear to be associated with a detrimental outcome. However these results are encouraging showing once again that with an adequate selection, age is not a definitive limitation. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
24. Comparison Of Umbilical Cord Blood and Haploidentical Donor Grafts In Adults With High Risk Hematologic Diseases After Fludarabine Cyclophosphamide and TBI 2 Gy Based Reduced-Intensity Conditioning Regimen Stem Cell Transplantation
- Author
-
Castagna Luca, Crocchiolo Roberto, Mohty Bilal, Santoro Armando, Chabannon Christian, Fürst Sabine, Didier Blaise, Granata Angela, Faucher Catherine, Bouabdallah Reda, Vey Norbert, Harbi Samia, Bramanti Stefania, El-Cheikh Jean, and Sarina Barbara
- Subjects
medicine.medical_specialty ,Cyclophosphamide ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Umbilical cord ,Fludarabine ,Transplantation ,Regimen ,Graft-versus-host disease ,medicine.anatomical_structure ,Internal medicine ,Cord blood ,medicine ,Cumulative incidence ,business ,medicine.drug - Abstract
Introduction Human leukocyte antigens (HLA)-matched sibling or unrelated donor are available for around only 50-60% of patients. However, for patients without a suitably matched related donor, Alternative donors such as mismatched unrelated, cord blood and mismatched family donors could be searched. The aim of this retrospective study was to compare the results of graft source on outcome of patients after haploidentical related donor (Haplo), and the unrelated umbilical cord blood (UCB) transplantation in the setting of Non myeloabalative conditioning regimen (NMA). Patients and methods We retrospectively analyzed outcomes in 150 adult patients with high risk hematologic diseases who received Allo-SCT from alternative donors from two centers (Institut Paoli-Calmettes at Marseille France and Humanitas cancer center at Rozzano, Italy): These two centres have been applying common transplant approaches and procedures during the study period. 69 patients received Haplo and 81 patients received UCB. In the UCB group, the NMA regimen consisted of fludarabine (Flu), cyclophosphamide (Cy) and low dose TBI (2 Gy) combination in the two groups. The GVHD prophylaxis consisted of Cyclosporine A (CsA) and MMF in all patients in the two groups. In the Haplo group all patients received also 50 mg/kg Cy at day 3 and 4 post transplant. Of note, supportive care was the same during the whole study period. CMV infection management was also homogeneous. Patient characteristics are shown in Table 1. Table 1 . Patient and transplantation characteristics: Characteristic Total =150 patients Haplo transplant (n = 69) CB transplant (n = 81) P value Patients Age years (median) [range] 44 (19-68) 47 (18-66) Patients sex ns Male 39 (57) 46 (57) Female 30 (43) 35 (43) Disease type AML 3 (4) 37 (46) ALL 1 (1) 14 (17) NHL 24 (35) 14 (17) ns HL 30 (43) 2 (2) MM 4 (6) 2 (2) ns CLL 5 (7) 4 (5) ns CML 0 1 (1) ns MDS/ MPS 2 (3) 7 (9) ns Status of disease CR 37 (54) 56 (69) ns PR/SD 24 (35) 12 (15) 0.04 PD 8 (11) 13 (16) ns Donor type Sibiling 32 (46) Parent 18 (26) Child 18 (26) cousin 1 (2) Donor/recipient sex mis-match 34 (49) 56 (69) ns ABO incompatibility 24 56 0.02 Conditioning regimen Flu 5+Cy 1+ TBI 0 75 (93) Flu 5+Cy 2+ TBI 69 (100) 6 (7) Stem cell source Peripheral Blood 19 (28) Bone Marrow 50 (72) Stem cell dose median [range] CD34+ x 106/kg 3,96 (0,8-14) 0,9 (0,08-1,28) GvHD prophylaxis CSA+MMF 69 (100) 81 (100) ns Cy post transplant 69 (100) 0 Days with ANC 20 (14-39) 22 (6-67) ns Days with platelets 29 (14-50) 41 (18-80) ns Results With a median follow-up of 59 months (8-101) and 18 months (3-51), in the UCB group versus the Haplo group, respectively. Nine patients (11%) in the UCB and 8 patients (12%) in the Haplo group had a spontaneous autologous reconstitution subsequent to primary graft failure. The median times to neutrophil and platelet recovery were 20 d (14–39) and 29 d (14–50) after Haplo and 22 d (6–67) and 41 d (18–80) after cord blood. All supportive care measures included red blood cell, and platelet transfusions were significantly increased in cord blood transplantation group. The cumulative incidence of transplant related mortality (TRM) at one year was 23% in the UCB group versus 17% in the Haplo group (P=0.39). Grade 2-4 acute graft-vs.-host disease (GVHD) and extensive chronic GVHD incidences were 52% versus 29% (P=0.05), and 12% versus 6% (P Conclusion In this study, relapse and PFS was lower in Haplo group than in UCB transplants. The main difference between the 2 groups was the significantly higher incidence of acute and chronic GVHD in the UCB group. Surprisingly, this did not translate into a decrease of the cumulative incidence of OS nor increase of the TRM, which may be explained by a slightly shorter follow-up in this group. Our results suggest that haploidentical transplants are a good and promising alternative option for patients with high risk hematological diseases who lack an HLA-matched donor (sibling or unrelated donor). This should be now investigated in prospective comparative studies. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
25. Plasma extracellular vesicles in cytomegalovirus reactivation after haploidentical stem cell transplantation
- Author
-
Lia, Giuseppe, Di Vito, Clara, Brunello, Lucia, Jacopo Mariotti, Zaghi, Elisa, Tapparo, Marta, Bruno, Stefania, Ciccone, Giovannino, Boccadoro, Mario, Evangelista, Andrea, Camussi, Giovanni, Castagna, Luca, Mavilio, Domenico, and Bruno, Benedetto
26. Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation
- Author
-
Castagna, Luca, Bramanti, Stefania, Busca, Alessandro, Malagola, Michele, Ciceri, Fabio, Arcese, William, Vallisa, Daniele, Patriarca, Francesca, Specchia, Giorgina, Raimondi, Roberto, Devillier, Raynier, Furst, Sabine, Giordano, Laura, Sarina, Barbara, Morabito, Lucio, Jacopo Mariotti, Granata, Angela, Bouabdallah, Reda, Carlo-Stella, Carmelo, Rambaldi, Alessandro, Santoro, Armando, Bacigalupo, Andrea, Corradini, Paolo, Bonifazi, Francesca, and Blaise, Didier
27. Donor specific anti-hla antibodies (DSA) in haploidentical stem cell transplantation with post transplant cyclophosphamide: Risk of graft failure, poor graft function and impact on outcomes
- Author
-
Bramanti, Stefania, Calafiore, Valeria, Longhi, Elena, Mariotti, Jacopo, Crespiatico, Loretta, Sarina, Barbara, Nocco, Angela, Philippis, Chiara, Armando Santoro, and Castagna, Luca
28. Feasibility of Modified CD45RA Negative Donor Lymphocytes Infusion after Haploidentical Stem Cell Transplantation (HAPLO-SCT) with Post-transplantation Cyclophosphamide (PT-Cy) in Patients with Hematological Malignancies
- Author
-
Bramanti, Stefania, Magri, Filippo, Paoli, Federica, Beek, Jasper, Barbara, Sarina, Timofeeva, Inna Anatolievna, Jacopo Mariotti, Capizzuto, Rossana, Chiara, Philippis, Mavilio, Domenico, Santoro, Armando, Lugli, Enrico, and Castagna, Luca
29. Efficacy and Safety of Donor Lymphocyte Infusions for Patients affected by Advanced Lymphoid Malignancies after Allogeneic Stem Cell Transplantation: A Retrospective Study
- Author
-
Diral, Elisa, Devillier, Raynier, Furst, Sabine, Granata, Angela, Bramanti, Stefania, Harbi, Samia, Mariotti, Jacopo, Philippis, Chiara, Sarina, Barbara, Pagliardini, Thomas, Maisano, Valerio, Piazza, Rocco, Bouabdallah, Reda, Carlo-Stella, Carmelo, Armando Santoro, Blaise, Didier, and Castagna, Luca
30. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: Outcome strongly correlates with disease status; a report from the EBMT acute leukemia working party
- Author
-
Bazarbachi, Ali, Labopin, Myriam, Angelucci, Emanuele, Gulbas, Zafer, Ozdogu, Hakan, Arat, Mutlu, Rosa, Luca, Tarella, Corrado, Pioltelli, Pietro, Montserrat, Rovira, Martino, Massimo, Ciceri, Fabio, Koc, Yener, Socie, Gerard, Didier Blaise, Herrera Arroyo, Concepcion, Chalandon, Yves, Bernasconi, Paolo, Marotta, Giuseppe, Castagna, Luca, Mcdonald, Andrew, Visani, Guiseppe, Specchia, Giorgina, Vitek, Antonin, Lioure, Bruno, Afanasyev, Boris, Roesler, Wolf, Diez-Martin, J. L., Nagler, Arnon, Brissot, Eolia, Giebel, Sebastian, and Mohty, Mohamad
31. NON-FIRST DEGREE RELATIVE DONOR AND THE OUTCOME OF PATIENTS RECEIVING T CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
- Author
-
Mariotti, Jacopo, Bramanti, Stefania, Brunello, Lucia, ANNA MARIA RAIOLA, Patriarca, Francesca, Martino, Massimo, Risitano, Antonio, Carella, Angelo Michele, Busca, Alessandro, Marotta, Serena, Merla, Emanuela, Bacigalupo, Andrea, Angelucci, Emanuele, Bruno, Benedetto, and Castagna, Luca
32. Gvhd after PBSC-Haploidentical Stem Cell Transplantation (Haplo-SCT) with Post Transplantation-Cyclophosphamide (PT-Cy)
- Author
-
Granata, Angela, Devillier, Raynier, Bramanti, Stefania, Furst, Sabine, Legrand, Faezeh, Harbi, Samia, Faucher, Catherine, Chabannon, Christian, Lemarie, Claude, Calmels, Boris, Jacopo Mariotti, Maisano, Valerio, Weiller, Pierre Jean, Castagna, Luca, and Blaise, Didier
33. The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg(-/-) Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts
- Author
-
Locatelli, Silvia Laura, Careddu, Giuseppa, Magagnoli, Massimo, Martina di Trani, Morello, Lucia, Viswanadha, Srikant, Vakkalanka, Swaroop Kumar V. S., Castagna, Luca, Santoro, Armando, and Carlo-Stella, Carmelo
34. The Minnesota Refined Acute GVHD Score Predicts Response to Initial Therapy, Survival and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
- Author
-
Mariotti, Jacopo, Granata, Angela, Devillier, Raynier, Bramanti, Stefania, Sarina, Barbara, Furst, Sabine, Faucher, Catherine, Harbi, Samia, Morabito, Lucio, Chabannon, Christian, Carlo-Stella, Carmelo, Bouabdallah, Reda, Santoro, Armando, Didier Blaise, and Castagna, Luca
35. Checkpoint inhibitor treatment before haploidentical transplantation in relapsed or refractory Hodgkin Lymphoma (HL) patients is associated with higher PFS without increased toxicities
- Author
-
Philippis, Chiara, Legrande, Faezeh, Bramanti, Stefania, Oca, C. Montes, Dulery, Remy, Bouabdallah, R., Granada, Angela, Devillier, Raynier, Mariotti, Jacopo, Sarina, Barbara, Harbi, Samia, Maisano, V., Furst, Sabine, Pagliardini, T., Weiller, P. J., Lemarie, Claude, Calmels, Boris, Chabannon, Christian, Carlo-Stella, Carmelo, Armando Santoro, Mohty, Mohamad, Blaise, Didier, and Castagna, Luca
36. Thiotepa, Fludarabine and Busulfan conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for AML and MDS : a bicentric experience of 109 patients
- Author
-
Pagliardini, Thomas, Castagna, Luca, Harbi, Samia, Rey, Jerome, Furst, Sabine, Bramanti, Stefania, Legrand, Faezeh, Maisano, Valerio, Faucher, Catherine, Granata, Angela, Weiller, Pierre-Jean, Calmels, Boris, Lemarie, Claude, Chabannon, Christian, Vey, Norbert, Didier Blaise, and Devillier, Raynier
37. Post-transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Versus Haploidentical Transplantation: A Retrospective Study on Behalf of The Acute Leukemia Working Party of The EBMT
- Author
-
Battipaglia, Giorgia, Galimard, Jacques-Emmanuel, Labopin, Myriam, Angelucci, Emanuele, Didier Blaise, Ruggeri, Annalisa, Gulbas, Zafer, Luiz Diez-Martin, Jean, Koc, Yener, Castagna, Luca, Vitek, Antonin, Chiusolo, Patrizia, Bruno, Benedetto, Moiseev, Ivan, Rovira, Montserrat, Martino, Massimo, Colorado Araujo, Mercedes, Arat, Mutlu, Grillo, Giovanni, Martin, Hans, Lopez Corral, Lucia, Pane, Fabrizio, Bazarbachi, Ali, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad
38. Primary Antifungal Prophylaxis with caspofungin after haploidentical transplantation with post-transplant cyclophosphamide: a retrospective analysis
- Author
-
Mariotti, Jacopo, Philippis, Chiara, Bramanti, Stefania, Sarina, Barbara, Tordato, Federica, Pocaterra, Daria, Erminia Casari, Carlo-Stella, Carmelo, Santoro, Armando, and Castagna, Luca
39. Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)
- Author
-
Locatelli, Silvia L., Papait, Roberto, Careddu, Giuseppa, Koschorke, Ada, Stirparo, Giuliano G., Balzarotti, Monica, Castagna, Luca, Armando Santoro, and Carlo-Stella, Carmelo
40. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT
- Author
-
Zafer Gulbas, Luca Castagna, J. L. Diez-Martin, Mohamad Mohty, Annalisa Ruggeri, Patrizia Chiusolo, Yener Koc, Didier Blaise, Benedetto Bruno, Arnon Nagler, Myriam Labopin, Massimo Martino, Mutlu Arat, Fabio Ciceri, Emanuele Angelucci, Ruggeri, Annalisa, Labopin, Myriam, Angelucci, Emanuele, Blaise, Didier, Ciceri, Fabio, Koc, Yener, Chiusolo, Patrizia, Diez-Martin, Jose Luiz, Gülbas, Zafer, Castagna, Luca, Bruno, Benedetto, Arat, Mutlu, Martino, Massimo, Nagler, Arnon, and Mohty, Mohamad
- Subjects
Myeloid ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,Neutrophils ,Graft vs Host Disease ,Acute ,Gastroenterology ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Retrospective Studies ,Transplantation ,Neutrophil Engraftment ,Leukemia ,business.industry ,Incidence (epidemiology) ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Prognosis ,Leukemia, Myeloid, Acute ,Hematology ,Regimen ,surgical procedures, operative ,medicine.anatomical_structure ,Bone marrow ,Stem cell ,business ,medicine.drug - Abstract
The use of haplo-HCT with posttransplant cyclophosphamide (PT-Cy) is a new standard in the treatment of hematological diseases. A paucity of data exists on risk factors for engraftment failure in haplo-HCT with PT-Cy. We analyzed 1939 adults with acute myeloid leukemia (AML) who received a first haplo-HCT from 2010 to 2019. Status at haplo-HCT was first complete remission (CR1) in 72.5% of patients, secondary AML was reported in 9.9%. Median follow-up was 24.4 months and median age at haplo-HCT was 51 years. Stem cell source was bone marrow (BM) in 42% and peripheral blood stem cell (PBSC) in 58%, and 64% of patients received a myeloablative conditioning (MAC) regimen. Cumulative incidence of primary graft failure (GF) was 6%; GF was reported in 110 patients and 54 died before day +30 with no sign of cell recovery. Overall, 33 patients underwent a second HCT in a median time of 45 days and 13 were alive at last follow-up, the 2-year overall survival (OS) after second HCT being 32.4%. In multivariate analysis, factors independently associated with the risk of nonengraftment were: secondary AML (HR 1.30, p = 0.003), use of RIC (HR 1.22, p
- Published
- 2021
41. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study
- Author
-
Johanna Tischer, Stella Santarone, Gerhard Ehninger, Audrey Mailhol, Yener Koc, Luca Castagna, Myriam Labopin, Emmanuelle Polge, Annalisa Ruggeri, Edouard Forcade, Fabio Ciceri, Arnon Nagler, Mohamad Mohty, Zhuoyan Li, Bipin N. Savani, M. T. Van Lint, Didier Blaise, Li, Zhuoyan, Labopin, Myriam, Ciceri, Fabio, Blaise, Didier, Tischer, Johanna, Ehninger, Gerhard, Van Lint, M. T., Koc, Yener, Santarone, Stella, Forcade, Edouard, Castagna, Luca, Polge, Emmanuelle, Mailhol, Audrey, Ruggeri, Annalisa, Mohty, Mohamad, Savani, Bipin N., Nagler, Arnon, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IRCCS Ospedale San Raffaele [Milan, Italy], Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Internal Medicine III [Munich, Germany], Hematopoietic Stem Cell Transplantation [Munich, Germany], Ludwig Maximilian University [Munich] (LMU)-Ludwig Maximilian University [Munich] (LMU), Technische Universität Dresden = Dresden University of Technology (TU Dresden), Stem Cell Transplant Unit [Antalya, Turkey], Medical Park Antalya Hospital [Turkey], Department of Hematology [Pescara, Italy], Bone Marrow Transplant Center [Pescara, Italy]-Ospedale Civile - BMT Center [Pescara, Italy], Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Département d'Hématologie [Marseille], Unité de Transplantation et de Thérapie Cellulaire [Marseille], Transplant Unit [Milano, Italy] (Department of Hemato-oncology), Humanitas Cancer Center [Milano, Italy], European Society for Blood and Marrow Transplantation (EBMT), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,[SDV]Life Sciences [q-bio] ,Graft vs Host Disease ,Relapse free survival ,Lymphocyte Depletion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Secondary Acute Myeloid Leukemia ,Aged ,Acute leukemia ,Haploidentical transplantation ,Performance status ,business.industry ,Marrow transplantation ,Hematopoietic Stem Cell Transplantation ,Neoplasms, Second Primary ,Hematology ,Middle Aged ,3. Good health ,Transplantation ,Leukemia, Myeloid, Acute ,Treatment Outcome ,surgical procedures, operative ,030220 oncology & carcinogenesis ,Transplantation, Haploidentical ,Female ,business ,030215 immunology ,medicine.drug - Abstract
International audience; Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values
- Published
- 2018
42. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT
- Author
-
Gloria Tridello, Johanna Tischer, Roberto Crocchiolo, Jan Styczyński, Pietro Pioltelli, Didier Blaise, Yener Koc, Franca Fagioli, Luca Castagna, J. L. Diez-Martin, Mahmoud Aljurf, Nina Knelange, Angelo Michele Carella, Gerhard Ehninger, Per Ljungman, Maria Teresa Van Lint, Boris V. Afanasyev, Arnon Nagler, Zafer Gulbas, Mutlu Arat, Benedetto Bruno, Mario Delia, Giuseppe Irrera, Malgorzata Mikulska, Luca Pierelli, Fabio Ciceri, Hakan Ozdogu, Simone Cesaro, Mohamad Mohty, Cesaro, Simone, Crocchiolo, Roberto, Tridello, Gloria, Knelange, Nina, van Lint, Maria Teresa, Koc, Yener, Ciceri, Fabio, Gülbas, Zafer, Tischer, Johanna, Afanasyev, Bori, Bruno, Benedetto, Castagna, Luca, Blaise, Didier, Mohty, Mohamad, Irrera, Giuseppe, Diez-Martin, J. L., Pierelli, Luca, Pioltelli, Pietro, Arat, Mutlu, Delia, Mario, Fagioli, Franca, Ehninger, Gerhard, Aljurf, Mahmoud, Carella, Angelo Michele, Ozdogu, Hakan, Mikulska, Malgorzata, Ljungman, Per, Nagler, Arnon, and Styczynski, Jan
- Subjects
Male ,Cytomegalovirus ,Gastroenterology ,Serology ,0302 clinical medicine ,hemic and lymphatic diseases ,Young adult ,tacrolimus ,Child ,Acute leukemia ,Leukemia ,haplo-HSCT, CMV status, clinical outcome ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Tissue Donors ,hematopoietic stem cell transplantation cytomegalovirus ,030220 oncology & carcinogenesis ,Child, Preschool ,Acute Disease ,Cytomegalovirus Infections ,Hematology, Transplantation ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Cyclophosphamide ,Adolescent ,survival ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Humans ,Serologic Tests ,cyclosporine ,Survival analysis ,Aged ,Transplantation ,business.industry ,mycophenolate mofetil ,Infant ,Survival Analysis ,Tacrolimus ,Transplantation, Haploidentical ,hematopoietic stem cell transplantation cytomegalovirus, survival ,business ,Serostatus ,030215 immunology - Abstract
The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide (PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT registered in the EBMT database. The 1-year NRM was 21.3% (95% CI: 18.4-24.8) and 18.8% (95% CI: 13.8-25.5) in the CMV D+/R+ and D-/R+ pairs, respectively (p = 0.40). Similarly, 1-year OS was 55.1% (95% CI: 50.1-58.0) and 55.7% (95% CI: 48.0-62.8) in the same groups (p = 0.50). The other main outcomes were comparable. No difference in NRM nor OS was observed after stratification for the intensity of conditioning and multivariate anaysis confirmed the lack of significant association with NRM or OS. In conclusion, the choice of a CMV-seronegative donor did not impair early survival of CMV-seropositive patients with acute leukemia after a first, non T-cell depleted haploidentical HSCT and PT-Cy among this series of 983 consecutive patients. Future research may focus on the assessment of the hierarchy of all the donor variables. © 2017 Macmillan Publishers Ltd., part of Springer Nature.
- Published
- 2018
43. New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?
- Author
-
Fabio Ciceri, Paolo Corradini, Renato Fanin, Renato Bassan, Stefano Volpetti, Antonio M. Risitano, Elena Maino, Benedetto Bruno, Nicola Mordini, Francesco Onida, Francesca Bonifazi, Raffaella Greco, Francesca Patriarca, Barbara Sarina, Luca Castagna, Jacopo Peccatori, Vittorio Montefusco, Michele Baccarani, Luisa Giaccone, Francesco Zaja, Alberto Mussetti, Moreno Festuccia, Alessandro Rambaldi, Patriarca, Francesca, Giaccone, Luisa, Onida, Francesco, Castagna, Luca, Sarina, Barbara, Montefusco, Vittorio, Mussetti, Alberto, Mordini, Nicola, Maino, Elena, Greco, Raffaella, Peccatori, Jacopo, Festuccia, Moreno, Zaja, Francesco, Volpetti, Stefano, Risitano, Antonio, Bassan, Renato, Corradini, Paolo, Ciceri, Fabio, Fanin, Renato, Baccarani, Michele, Rambaldi, Alessandro, Bonifazi, Francesca, Bruno, Benedetto, and Risitano, ANTONIO MARIA
- Subjects
Oncology ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Clinical Biochemistry ,Pharmaceutical Science ,Salvage therapy ,Allogeneic stem cell transplantation ,graft-versus-tumor ,monoclonal antibodies ,new drugs ,targeted therapy ,Pharmacology ,Drug Discovery3003 Pharmaceutical Science ,Graft vs Host Disease ,Antineoplastic Agents ,Disease ,Hematopoietic stem cell transplantation ,Monoclonal antibody ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Drug Discovery ,medicine ,Humans ,Transplantation, Homologous ,Single agent ,monoclonal antibodie ,Protein Kinase Inhibitors ,Salvage Therapy ,new drug ,business.industry ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Transplantation ,surgical procedures, operative ,030220 oncology & carcinogenesis ,Hematologic Neoplasms ,Immunology ,Stem cell ,business ,030215 immunology - Abstract
Introduction: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to âsmartlyâ combine âtargeted drugs and cell therapiesâ in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.
- Published
- 2017
44. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
- Author
-
Marie J Chammas, Emily Pesek, Robert J. Soiffer, Veronika Bachanova, Abraham Avigdor, Joseph H. Antin, Armando Santoro, Philippe Armand, Willy Lescaut, Anne Thiebaut-Bertrand, Stephen M. Ansell, Jerome Ritz, Pier Luigi Zinzani, Reid W. Merryman, Ahmad Halwani, Miguel-Angel Perales, Scott C. Bresler, Harim Kim, L. Castagna, Amitabh Srivastava, Vincent T. Ho, Haesook T. Kim, Roch Houot, Aspasia Stamatoullas-Bastard, Carol Reynolds, Pierre-Simon Rohrlich, Carmelo Carlo-Stella, Nathalie Dhedin, Hélène Labussière Wallet, Tony Marchand, Sylvie François, Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Wallet, Hélène Labussière, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., Armand, Philippe, Service d'hématologie clinique, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Princesse Grace de Monaco (CHPG), Monaco, Clinique Universitaire d'Hématologie [La Tronche, Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service des maladies du sang [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Hôpital l'Archet, Hospices Civils de Lyon (HCL), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Department of Oncology and Hematology, Humanitas Cancer Center, University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Harvard Medical School [Boston] (HMS), Seoul National University College of Medicine, Dana-Farber Cancer Institute [Boston], L. and A. Seràgnoli Hospital, University of Bologna, University of Milan, Mayo Clinic [Rochester], Memorial Sloane Kettering Cancer Center [New York], Chaim Sheba Medical Center, Huntsman Cancer Institute [Salt Lake City], University of Utah, Université de Rennes (UR)-Hôpital Pontchaillou, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Università degli Studi di Milano = University of Milan (UNIMI), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), and University of Minnesota [Twin Cities]
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lymphoma ,medicine.medical_treatment ,Immunology ,Programmed Cell Death 1 Receptor ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Biochemistry ,Disease-Free Survival ,Statistics, Nonparametric ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Immune system ,Internal medicine ,medicine ,Cytotoxic T cell ,Humans ,Aged ,Retrospective Studies ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Hematology ,Cell Biology ,Middle Aged ,medicine.disease ,Allografts ,Combined Modality Therapy ,3. Good health ,Blockade ,Nivolumab ,030220 oncology & carcinogenesis ,Monoclonal ,Female ,Neoplasm Recurrence, Local ,business ,030215 immunology - Abstract
International audience; Anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). However, the safety and efficacy of HSCT may be affected by prior PD-1 blockade. We conducted an international retrospective analysis of 39 patients with lymphoma who received prior treatment with a PD-1 inhibitor, at a median time of 62 days (7-260) before HSCT. After a median follow-up of 12 months, the 1-year cumulative incidences of grade 2-4 and grade 3-4 acute graft-versus-host disease (GVHD) were 44% and 23%, respectively, whereas the 1-year incidence of chronic GVHD was 41%. There were 4 treatment-related deaths (1 from hepatic sinusoidal obstruction syndrome, 3 from early acute GVHD). In addition, 7 patients developed a noninfectious febrile syndrome shortly after transplant requiring prolonged courses of steroids. One-year overall and progression-free survival rates were 89% (95% confidence interval [CI], 74-96) and 76% (95% CI, 56-87), respectively. One-year cumulative incidences of relapse and nonrelapse mortality were 14% (95% CI, 4-29) and 11% (95% CI, 3-23), respectively. Circulating lymphocyte subsets were analyzed in 17 patients. Compared with controls, patients previously treated with PD-1 blockade had significantly decreased PD-1(+) T cells and decreased ratios of T-regulatory cells to conventional CD4 and CD8 T cells. In conclusion, HSCT after PD-1 blockade appears feasible with a low rate of relapse. However, there may be an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD-1 blockade.
- Published
- 2017
45. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
- Author
-
Gwendolyn Van Gorkom, Patrice Chevallier, Nicolaus Kröger, Fabio Ciceri, Carol Moreno, Johannes Schetelig, Henric-Jan Blok, Paolo Corradini, Roberto Foa, Yener Koc, M. T. Van Lint, Dietrich W. Beelen, Didier Blaise, Johanna Tischer, Dominik Selleslag, Lutz P. Müller, Inken Hilgendorf, Joerg Thomas Bittenbring, Matthias Theobald, Dirk-Jan Eikema, Michel van Gelder, Michael Hallek, Carlos Solano, Luca Castagna, van Gorkom, Gwendolyn, van Gelder, Michel, Eikema, Dirk-Jan, Blok, Henric-Jan, van Lint, M. T., Koc, Yener, Ciceri, Fabio, Beelen, Dietrich, Chevallier, Patrice, Selleslag, Dominik, Blaise, Didier, Foá, Roberto, Corradini, Paolo, Castagna, Luca, Moreno, Carol, Solano, Carlo, Müller, Lutz Peter, Tischer, Johanna, Hilgendorf, Inken, Hallek, Michael, Bittenbring, Jörg, Theobald, Matthia, Schetelig, Johanne, Kröger, Nicolaus, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Promovendi ODB, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
Oncology ,Male ,BLOOD ,Chronic lymphocytic leukemia ,medicine.medical_treatment ,Medizin ,MULTICENTER ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Medicine ,POSTTRANSPLANTATION CYCLOPHOSPHAMIDE ,Cumulative incidence ,ALLOGENEIC TRANSPLANTATION ,DONOR TRANSPLANTATION ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,EUROPEAN-SOCIETY ,surgical procedures, operative ,Treatment Outcome ,Transplantation ,030220 oncology & carcinogenesis ,SURVIVAL ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,Cyclophosphamide ,MINIMAL RESIDUAL DISEASE ,03 medical and health sciences ,Internal medicine ,Humans ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,medicine.disease ,Minimal residual disease ,BONE-MARROW-TRANSPLANTATION ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Transplantation, Haploidentical ,business ,CLL ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
- Published
- 2017
46. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
- Author
-
Sandro Barni, Simona Secondino, Francesco Lanza, Giovanni Rosti, Daniele Generali, Massimo Martino, Paolo Pedrazzoli, Alberto Bottini, Luca Castagna, Roberto Maisano, Martino, Massimo, Bottini, Alberto, Rosti, Giovanni, Generali, Daniele, Secondino, Simona, Barni, Sandro, Maisano, Roberto, Lanza, Francesco, Castagna, Luca, and Pedrazzoli, Paolo
- Subjects
Oncology ,medicine.medical_treatment ,High-risk breast cancer ,Clinical Biochemistry ,autologous transplantation ,Antineoplastic Agent ,high-risk breast cancer ,High dose chemotherapy ,stem cell mobilization and collection ,Autologous hematopoietic progenitor cell transplantation ,High-dose chemotherapy ,Metastatic breast cancer ,Animals ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Combined Modality Therapy ,Disease-Free Survival ,Dose-Response Relationship, Drug ,Female ,Hematopoietic Stem Cell Transplantation ,Humans ,Randomized Controlled Trials as Topic ,Transplantation, Autologous ,Pharmacology ,Drug Discovery3003 Pharmaceutical Science ,Medicine (all) ,Drug Discovery ,Transplantation, Autologou ,metastatic breast cancer ,Drug ,Autologous ,Breast Neoplasm ,Human ,medicine.medical_specialty ,NO ,Dose-Response Relationship ,Breast cancer ,Cell transplantation ,Internal medicine ,medicine ,Overall survival ,Chemotherapy ,Transplantation ,autologous hematopoietic progenitor cell transplantation ,Antineoplastic Combined Chemotherapy Protocol ,autologous hematopoietic progenitor cell transplantation, high-dose chemotherapy, high-risk breast cancer, metastatic breast cancer, stem cell mobilization and collection, autologous transplantation ,business.industry ,Animal ,medicine.disease ,Clinical trial ,Hematopoietic progenitor ,business ,high-dose chemotherapy - Abstract
INTRODUCTION: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. AREAS COVERED: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. EXPERT OPINION: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.